Data Integrity in the Pharma Space

Pharmaceutical companies and contract manufacturing organizations must work within Good Manufacturing or Laboratory Practice regulations to ensure the safety and quality of pharmaceutical products. Yet over the past 15 years, there have been many data integrity breaches. Now, regulatory authorities are encouraging pharmaceutical companies to work electronically to ensure data integrity.

Spotlight

AL ANDALOUS PHARMACEUTICAL SERVICES ( APS )

Al Andalous Pharmaceutical Services (APS) a privately owned Egyptian company, established in 2006 with a two-fold mission: - Partner with international innovative pharmaceutical and medical device companies to bring innovative specialty products to Egypt and ME region - Provide world-class services and consulting to pharmaceutical industry - focus on regulatory , government affairs and clinical research services APS combines local expertise and access with a multinational perspective, building on the existing leadership and strong position of sister company Al Andalous Medical Company in the Egyptian market.

OTHER WHITEPAPERS
news image

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More
news image

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More
news image

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Read More
news image

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Read More
news image

Demystifying content marketing for the pharma industry

whitePaper | November 10, 2022

We know people don’t like to be sold to. And in the so-called ‘attention economy’, it is more important than ever that your business can utilise meaningful marketing and advertising practices to engage with your customers and secure their attention.

Read More

Spotlight

AL ANDALOUS PHARMACEUTICAL SERVICES ( APS )

Al Andalous Pharmaceutical Services (APS) a privately owned Egyptian company, established in 2006 with a two-fold mission: - Partner with international innovative pharmaceutical and medical device companies to bring innovative specialty products to Egypt and ME region - Provide world-class services and consulting to pharmaceutical industry - focus on regulatory , government affairs and clinical research services APS combines local expertise and access with a multinational perspective, building on the existing leadership and strong position of sister company Al Andalous Medical Company in the Egyptian market.

Events